Valuation : Dermata Therapeutics, Inc.

Market Cap 4.83M 4.15M 3.92M 3.57M 6.67M 461M 6.73M 46.64M 17.95M 234M 18.12M 17.73M 743M P/E 2026 *
-0.55x
P/E 2027 * -0.84x
Enterprise Value 4.83M 4.15M 3.92M 3.57M 6.67M 461M 6.73M 46.64M 17.95M 234M 18.12M 17.73M 743M EV / Sales 2026 *
48.3x
EV / Sales 2027 * 6.44x
Free-Float
72.65%
Yield 2026 *
-
Yield 2027 * -
1 day-0.83%
1 week-2.44%
Current month-6.98%
1 month+7.14%
3 months+0.84%
6 months-5.51%
Current year-48.28%
1 week 1.18
Extreme 1.18
1.31
1 month 1.18
Extreme 1.18
1.72
Current year 0.95
Extreme 0.9509
4.66
1 year 0.95
Extreme 0.9509
6.22
3 years 0.95
Extreme 0.9509
175.5
5 years 0.95
Extreme 0.9509
16,679.99
10 years 0.95
Extreme 0.9509
16,679.99
Manager TitleAgeSince
Chief Executive Officer 67 08/12/2014
Director of Finance/CFO 48 01/09/2021
Investor Relations Contact - -
Director TitleAgeSince
Chairman 67 01/04/2021
Director/Board Member 77 08/12/2014
Director/Board Member 78 20/09/2016
Date Insider Type Main position Quantity % Market Cap. Importance
16/08/26 Free

Chief Financial Officer

306,120 10.7966%
17/02/26 Buy

General Counsel

1,000 0.0353%
02/01/26 Free

Director

2,500 0.0940%
Change 5-day change 1-year change 3-year change Capi.($)
-0.83%-2.44%-78.18%-99.27% 4.83M
-0.25%-1.36%+44.08%+102.76% 68.24B
-1.09%-6.20%+30.50%+76.56% 62.23B
-1.18%+0.47%-12.78%+384.69% 27.8B
-1.98%-5.25%+29.44%+9.13% 24.86B
-1.76%-6.30%-4.55%-19.75% 24.22B
-2.39%-5.19%+17.75%-20.95% 19.36B
-1.86%-2.22%+202.03%+353.89% 17.28B
-1.64%-4.62%-4.97%+497.70% 14.46B
-1.54%-2.88%+52.33%+159.75% 14.23B
Average -1.44%-3.22%+27.57%+144.45% 27.27B
Weighted average by Cap. -1.21%-3.10%+35.50%+137.15%

Financials

2026 *2027 *
Net sales 100K 86K 81.14K 73.92K 138K 9.56M 139K 966K 372K 4.85M 376K 367K 15.4M 750K 645K 609K 554K 1.04M 71.71M 1.05M 7.25M 2.79M 36.37M 2.82M 2.75M 116M
Net income -11.08M -9.53M -8.99M -8.19M -15.32M -1.06B -15.45M -107M -41.22M -537M -41.62M -40.71M -1.71B -13.78M -11.85M -11.18M -10.19M -19.05M -1.32B -19.22M -133M -51.26M -668M -51.76M -50.63M -2.12B
Net Debt - -
Logo Dermata Therapeutics, Inc.
Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases.
Employees
9
Date Price Change Volume
10/09/26 $1.200 -0.83% 16,420
09/09/26 $1.210 -3.20% 18,413
08/09/26 $1.250 +3.31% 51,184
04/09/26 $1.210 -1.63% 40,555
03/09/26 $1.230 -3.91% 101,903
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.200USD
Average target price
4.000USD
Spread / Average Target
+233.33%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DRMA Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!